Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 December;61(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 December;61(4):360-71

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

REVIEW  NEWS AND VIEWS ON CLINICAL NEUROIMAGINGFREEfree


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 December;61(4):360-71

DOI: 10.23736/S1824-4785.17.03011-4

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Imaging biomarkers in Alzheimer’s disease: added value in the clinical setting

Silvia MORBELLI 1, 2 , Matteo BAUCKNEHT 1, 2, Philip SCHELTENS 3

1 Unit of Nuclear Medicine, San Martino Polyclinic Hospital, Genoa, Italy; 2 Department of Health Sciences (DiSSAL), University of Genoa, Genoa, Italy; 3 Alzheimer Center, Department of Neurology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands


PDF  


Over the last 20 years the availability of magnetic resonance imaging and positron-emission tomography technologies as well as of cerebrospinal fluid biomarkers has allowed research and clinical approach to Alzheimer’s disease (AD) to move towards the earliest manifestations of the disease. This new approach resulted in an increasing knowledge about in-vivo biological and neuropathological processes of each phase of the AD-related damage from preclinical, to mild cognitive impairment, and finally to dementia due to AD. The present narrative review deals with the available data as well as with the unsolved issued related to the incorporation of AD biomarkers into the clinical practice. Ongoing research efforts aiming to better define and implement the use of imaging AD biomarkers in clinical practice according to a patient-centered approach and sustainability for clinical-care systems are also discussed.


KEY WORDS: Alzheimer disease - Positron-emission tomography - Nerve degeneration - Amyloidosis

top of page

Publication History

Issue published online: September 20, 2017
Article first published online: July 27, 2017
Manuscript accepted: July 25, 2017
Manuscript received: July 3, 2017

Cite this article as

Morbelli S, Bauckneht M, Scheltens P. Imaging biomarkers in Alzheimer’s disease: added value in the clinical setting. Q J Nucl Med Mol Imaging 2017;61:360-71. DOI: 10.23736/S1824-4785.17.03011-4

Corresponding author e-mail

silviadaniela.morbelli@hsanmartino.it